| Species |
Cynomolgus |
| Protein Construction |
| Flag |
His |
APRIL/TNFSF13 Trimer (Lys112-Leu250)
Accession # A0A2K5TJA1 |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1 EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized APRIL/TNFSF13 Trimer, His & Avi & Flag, Cynomolgus at 1μg/ml (100μl/well) on the plate can bind Cynomolgus/Rhesus macaque BCMA, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
52.1 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, 200 mM L-arginine (pH 8.0). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Immobilized APRIL/TNFSF13 Trimer, His & Avi & Flag, Cynomolgus, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Cynomolgus BCMA, hFc Tag with the EC50 of 1.4 ng/ml determined by ELISA.
APRIL/TNFSF13 Trimer, His & Avi & Flag, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
| Target Background |
The APRIL (a proliferation-inducing ligand), also known as TNFSF13, TALL2, TRDL1, and CD256, is a member of the TNF ligand superfamily. Both APRIL and its close relative BAFF bind and signal through the TNF superfamily receptors TACI and BCMA, while BAFF additionally functions through BAFFR. |
| Synonyms |
CD256; TALL2; TALL-2; TNFSF13; APRIL; APRILFLJ57090; TRDL1; TRDL-1; ZTNF2; 2310026N09Rik |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
